Yeah they've given 50% away but have gained in so many more ways imo. I'm away ATM so can't go as indepth as I'd want to, there's fishing, snorkling, boating and beer to be done
This is just for Japan and they also get their 50% cut on any sublicensing and additional indications. They have also gained a very valuable partner/manufacturer/funder who knows and operates in the Japanese market and knows the regulatory landscape and pharmaceutical industry players, they also have manufacturing capabilities in Europe and the US which could become quite useful in the future!
I think it best, as a small player, to partner and have the nessesary funding to timely achieve market share and presence, how many times have we seen good ideas/tech/science go to waste due to low level access to funding, small teams running on oily rags and nothing getting done in a timely manner to gain market share and access, I think that's most of the Aussie biotech sector!
There's much more the company has also and can concentrate on those opportunities as well, especially now funding and manufacturing is taken care of!
There's more to say but for now I need another beer and have to have a talk to these annoying Island cockatoos who are making a racket
Have a good one all, I did expect more of a bounce but that shall come I'd say.
RGS Price at posting:
18.5¢ Sentiment: Buy Disclosure: Held
